Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.32 |
| ▸ | ENTPD2 | Q9Y5L3 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7209723 | 1.00 | TDP1 (0.38) | TDP1NT5EP2RY2P2RY4P2RY6 | |
| SCHEMBL23054812 | 1.00 | TDP1 (0.38) | TDP1NT5EP2RY2P2RY4P2RY6 | |
| SCHEMBL7214757 | 0.89 | NT5E (0.37) | NT5EP2RY2P2RY4P2RY6P2RY12 | |
| SCHEMBL23054811 | 0.89 | NT5E (0.37) | NT5EP2RY2P2RY4P2RY6P2RY12 | |
| SCHEMBL22609161 | 0.89 | TK1 (0.36) | — | |
| SCHEMBL22609159 | 0.89 | TK1 (0.36) | — | |
| SCHEMBL23054795 | 0.89 | TK1 (0.36) | — | |
| SCHEMBL25401110 | 0.88 | TSHR (0.32) | — | |
| SCHEMBL7214745 | 0.88 | TSHR (0.32) | — | |
| SCHEMBL7214746 | 0.87 | NT5E (0.43) | TDP1NT5EP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | TDP1 708/4885NT5E 141/4885P2RY2 480/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | TDP1 469/4885NT5E 188/4885P2RY2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.